At the board meeting on January 8, 2021, I was elected to succeed Professor Toshiyuki Someya and serve as the 10th president of the JSCNP. During my term of office, which will last until the end of the 32nd annual meeting scheduled to be held in Tokyo on November 4–6, 2022, I will do my utmost to guide the development of the society in cooperation with Vice President Koichiro Watanabe and the board members, councilors, and members of the society. I look forward to working closely with each and every one of you.
The JSCNP was established on November 19, 1981 at the first meeting of the Clinical Neuropsychopharmacology Study Group at Fukushima Medical University. The aim of the JSCNP is “to develop clinical neuropsychopharmacology and improve psychiatric pharmacotherapy.” The name of the organization was changed to the Society of Clinical Neuropsychopharmacology in 1994 and the Japanese Society of Clinical Neuropsychopharmacology in 1995. The JSCNP became a general incorporated association in 2010 and currently has more than 1,500 members. In addition, we have produced many outstanding professors and researchers in the field of psychiatry, and most importantly, are training the next generation of energetic, young people in this field.
Clinical neuropsychopharmacology is a scientific discipline that pursues the rational pharmacological treatment of psychiatric disorders by administering the right drug to the right patient group at the right dose in the right manner. To help members brush up their knowledge of psychiatric pharmacotherapy, the society discusses topics such as pharmacokinetics, pharmacodynamics, genome pharmacology, algorithms for pharmacotherapy, drug interactions, adverse events, clinical trials, and psychotropic drug development. We believe that cooperation with related academic societies and related fields is essential for the future activities and development of the JSCNP.
The main activities of the society are annual meetings, education and certification of clinical neuropsychopharmacology specialists, the Paul Janssen Award for the best paper of the year, overseas research training programs, and publication of Clinical Neuropsychopharmacology and Therapeutics, the official journal of our the JSCNP.
The educational functions of our society have been enhanced, and each of the clinical neuropsychopharmacology seminars and clinical psychopharmacology educational seminars explores clinically useful themes. We are also planning to provide educational content through e-learning and online seminars. In addition, the “Clinical Neuropsychopharmacology Textbook” published by the society will be revised and republished in March 2021 as the “Clinical Neuropsychopharmacology Textbook for Specialists.”
I would like to humbly ask for your support and cooperation in these endeavors.
Japanese Society of Clinical Neuropsychopharmacology